Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden.
(2009) In Clinical Ophthalmology 3. p.471-481- Abstract
- BACKGROUND: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden). METHODS: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated... (More)
- BACKGROUND: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden). METHODS: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis and a general practitioner survey. RESULTS: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for travoprost and travoprost/timolol. CONCLUSIONS: On taking into account drug costs and effectiveness, travoprost and travoprost/timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were cheaper than bimatoprost and bimatoprost/timolol. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1469252
- author
- Bergström, Anders LU ; Maurel, Frédérique ; Le Pen, Claude ; Lamure, Emilie ; Kent, Michael ; Bardoulat, Isabelle and Berdeaux, Gilles
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Ophthalmology
- volume
- 3
- pages
- 471 - 481
- publisher
- Dove Medical Press Ltd.
- external identifiers
-
- pmid:19714225
- scopus:77953383756
- ISSN
- 1177-5467
- language
- English
- LU publication?
- yes
- id
- d4e9b93d-1920-4454-8a96-c73d2737a859 (old id 1469252)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19714225?dopt=Abstract
- date added to LUP
- 2016-04-04 07:19:08
- date last changed
- 2022-01-29 02:00:29
@article{d4e9b93d-1920-4454-8a96-c73d2737a859,
abstract = {{BACKGROUND: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden). METHODS: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis and a general practitioner survey. RESULTS: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for travoprost and travoprost/timolol. CONCLUSIONS: On taking into account drug costs and effectiveness, travoprost and travoprost/timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were cheaper than bimatoprost and bimatoprost/timolol.}},
author = {{Bergström, Anders and Maurel, Frédérique and Le Pen, Claude and Lamure, Emilie and Kent, Michael and Bardoulat, Isabelle and Berdeaux, Gilles}},
issn = {{1177-5467}},
language = {{eng}},
pages = {{471--481}},
publisher = {{Dove Medical Press Ltd.}},
series = {{Clinical Ophthalmology}},
title = {{Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden.}},
url = {{http://www.ncbi.nlm.nih.gov/pubmed/19714225?dopt=Abstract}},
volume = {{3}},
year = {{2009}},
}